TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05410717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells
Description: Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.~In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells
Description: Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.~In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells
Description: Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.~In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells
Description: Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.~In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells
Description: Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.~In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy.
Study: NCT06393855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-step Trans-PRK
Description: Both eyes were treated consecutively in each patient by single-step Trans-PRK performed by SCHWIND Amaris 500 S excimer laser platform (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany). Topical Proparacaine Hydrochloride Eye Drops 0.5% (Alcaine, Alcon, Fort Worth, TX, USA) were used to anesthetize the eyes, and use povidone-iodine to disinfect the eyelid skin. After a lid speculum had been inserted, and the other eye was blocked. Epithelial and stromal ablations were performed using a single continuous laser shooting session on an excimer laser platform. After the appeals step, Mitomycin C 0.02 % was applied to the stromal surface for 20 s, then rinse with cold salt water.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-step Trans-PRK
Description: Both eyes were treated consecutively in each patient by single-step Trans-PRK performed by SCHWIND Amaris 500 S excimer laser platform (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany). Topical Proparacaine Hydrochloride Eye Drops 0.5% (Alcaine, Alcon, Fort Worth, TX, USA) were used to anesthetize the eyes, and use povidone-iodine to disinfect the eyelid skin. After a lid speculum had been inserted, and the other eye was blocked. Epithelial and stromal ablations were performed using a single continuous laser shooting session on an excimer laser platform. After the appeals step, Mitomycin C 0.02 % was applied to the stromal surface for 20 s, then rinse with cold salt water.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placing a bandage contact lens on the cornea, with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye.
Description: After surgery. A contact lens placed on the cornea, with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placing a bandage contact lens on the cornea,A contact lens placed on the cornea, with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye.
Description: After surgery. A contact lens placed on the cornea, with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye.
Study: NCT04636515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F520
Description: 200mg，Q3W
Study: NCT06244394

Intervention type: RADIATION
Intervention: intensity-modulated radiotherapy
Description: All patients were staged according to the 8th edition of the TNM classification by the American Joint Committee on Cancer/Union for International Cancer Control and received a standardized treatment regimen including IMRT and concurrent or adjuvant chemotherapy. Inverse IMRT treatment planning was performed on a Varian Inspiration Platform (version 10.0), using the simultaneous integrated boost technique. The prescribed doses were 68-75 Gy to the PTV of the GTVnx in 32-34 fractions; 64-75 Gy to the PTV of the GTVnd in 32-34 fractions; 60 Gy to the PTV of CTV1 in 32 fractions; and 50 Gy to the PTV of CTV2 in 28 fractions. All patients were given one fraction daily 5 days a week. The dose-volume-histograms (DVHs) of the organs at risk were evaluated as described in the radiation therapy oncology group (RTOG) 0225 protocol to prevent violation of the tolerance limits.
Study: NCT05336188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: Adjunctive Smartphone app for improving MAT outcomes
Study: NCT06367244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transplant Wellness Program - Kidney and Liver
Description: The exercise prescription for the intervention will be multimodal, , will follow current chronic disease exercise guidelines, and will be tailored to meet the unique needs of each participant. . All participants will receive two 30-45-minute individual session with a CEP during their first week and two additional sessions during the second week if needed. The individual sessions will be followed by group sessions. Each participant will get a total of 24 individual and group sessions combined. These sessions can be conducted either in-person or online, based on participant preference and TWP logistics. For aerobic-based activities, a moderate rate of perceived exertion of 4-6 on a scale of 0-10 will be used. Resistance exercise will begin with functional movements and bodyweight exercises targeting major muscle groups with modifications for beginners and exercise progressions when deemed. Balance and flexibility training activities will also be included.
Study: NCT05823857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Therapy
Description: Participants in this experimental intervention group will perform trunk stabilization, which will be based on a variety of aquatic exercises in different positions, intended to activate the multifidus and transverse abdominis in a co-contraction. Additionally, hip exercises will be completed to promote the strengthening of the gluteus maximus, gluteus medius, and gluteus minimus muscles. The aim of these exercises is to enhance the strength and dynamic stability of the spine and its surrounding musculature in a functional and yet non-weight-bearing way. Each exercise will be performed 10 times while sustaining the muscles co-contraction for 5-10 seconds and will be progressed gradually. Each training session (60 minutes) will be supervised by a Certified Athletic Therapist and take place in the PERFORM AT Clinic/Swim Ex pool.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Participants in this experimental intervention group will receive the standard LBP treatment in the PERFORM Athletic Therapy clinic.Two Certified Athletic Therapists (AT) will be conducting the sessions. The ATs will complete a thorough assessment of the eligible participants with chronic LBP and administer a range of interventions including stretching, strengthening and stabilization exercise, aerobic conditioning, and manual mobilization techniques. Other modalities could include application of ice and heat, ultrasound, and transcutaneous electrical nerve stimulation (TENS).
Study: NCT05651815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graphene spectrum light wave therapy room
Description: Undergo 30-min of graphene adjuvant therapy every day for 7 d.
Study: NCT06491784

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: 12 week personalised exercise, nutrition and wellbeing programme
Study: NCT06455865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TPACK-Based Blended Learning Instruction
Description: The control group employed traditional in-person teaching methods, including face-to-face classroom instruction, reading from printed textbooks, and completing homework assignments. The curriculum covered the fundamental theories and skills related to information resource retrieval and usage but did not specifically utilize the TPACK framework. Students primarily received lectures and guidance from the instructor during class and completed assignments and learning tasks independently after class.
Study: NCT04924270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation
Description: The capsule FMT transplant consists of faeces obtained from a thoroughly screened, unpaid, anonymous stool donor. Each FMT product is made from 50g faeces diluted in sterile saline (0.9% NaCl) and glycerol, blended, centrifuged and filtered to remove particulate material before transfer to double-layered capsules. The FMT capsules will be stored at - 80 ⁰C until use. On the day of the FMT, the FMT capsules will be thawed to room temperature before treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules consist of NaCl (0.9%) and glycerol added brown food colouring.
Study: NCT06185075

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant crown delivery
Description: Dental implant crown will be designed, fabricated by a dental lab, and delivered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant crown delivery
Description: Dental implant crown will be designed, fabricated by a dental lab, and delivered.
Study: NCT06244264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autoblood transfusion
Description: Through a negative pressure suction device, the patient's blood that flows out during surgery is collected into a blood storage filter. During the suction process, it is mixed with an appropriate anticoagulant and passed through multiple layers of filters. When the volume of recovered blood reaches a certain level, it is continuously (or intermittently) centrifuged. Using a high-speed centrifugal blood recovery tank, the red blood cells are separated, and the plasma, waste, cell fragments, anticoagulants, and harmful components are diverted into a waste bag. A large amount of saline is used to repeatedly wash, purify, and concentrate the red blood cells. Finally, the concentrated red blood cells are prepared into a 70% red blood cell suspension with saline and stored in a collection bag for transfusion back to the patients. Open surgery is considered as the standard procedure for metastatic spinal cord compression
Study: NCT06215963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App for Independence-O (A4i-O)
Description: A4i-O is a digital health platform designed to support individuals with opioid use disorders. A4i-O will focus on providing education on treatment options, recovery navigation, social activation and connections to a range of resources. It aims to assist with fostering self-management and recovery through identifying risks for relapse, navigating urges/cravings, coping with shame/guilt, avoiding relapse, moving forward after relapse, and lived experiences. Daily wellness and goal attainment check-ins to highlight mental health trajectories will be prompted. With appropriate consent from both the client and provider, a provider dashboard is accessible to the client's provider prior to their appointment, generating a summary of day-to-day wellness ratings, responses to reminders, goal progressions, and other self-reported measures from the platform.
Study: NCT05960006

Intervention type: OTHER
Intervention: No intervention
Description: There are no risks associated with participation because only waste material (blood and ascites) will be used for analysis and no additional blood collection or paracentesis will be performed in addition to standard-of-care. Moreover, hospital admittance and discharge, indication for interventional procedures, indication/initiation/duration/dosing of ceftriaxone, indication/timing/frequency of blood withdrawal for standard of care biochemical analysis and microbiological culturing as the indication, timing, frequency and duration of paracentesis are all decided by the treating physician independent of participation in the study. There are no extra site visits nor extra days of hospital admission. There is no direct benefit for participants of this explorative study. .
Study: NCT06254287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag was given 40 mg/ time, once a day, orally, for 3 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Avatrombopag +rhTPO
Description: Avatrombopag: 40 mg/ time, once a day, orally; rhTPO: 15000U/ time, once a day, subcutaneous injection; Both were 3 months.
Study: NCT06327399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine infusion
Description: patients will receive Dexmedetomidine infusion dose of 1 mcg/kg over 10 min before induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine bolus
Description: patients will receive Dexmedetomidine bolus dose of 0.3 mcg/kg over 60 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate
Description: If heart rate falls below 45 bpm, rescue dose (500 mcg) of atropine will be given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate
Description: If heart rate falls below 45 bpm, rescue dose (500 mcg) of atropine will be given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: If mean blood pressure decreases below 50 mmHg, boluses of 10 mg ephedrine will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: If mean blood pressure decreases below 50 mmHg, boluses of 10 mg ephedrine will be given
Study: NCT04347629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Care Planning Video Decision Aid
Description: The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
Study: NCT05814965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endodontic treatment in the form of root canal treatment
Description: Patients will receive endodontic treatment, and inflammatory markers will be assessed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endodontic treatment
Description: Patients will receive endodontic treatment in the form of root canal treatment, and inflammatory markers will be assessed along with metabolic markers assessment

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: assessment of inflammatory marker
Description: assessment of inflammatory markers

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: inflammatory markers will be assessed along with metabolic markers assessment
Description: inflammatory markers will be assessed along with metabolic markers assessment
Study: NCT04794530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cocoa flavanols
Description: The cocoa flavanols intervention is manufactured by Mars Inc. Participants randomized to cocoa flavanols will take two capsules daily of cocoa flavanols. The two capsules of cocoa flavanols will contain approximately 500 mg of cocoa flavanols and appoximately 80 mg of (-)-epicatechin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo intervention will be manufactured by Mars Inc. and will appear identical to the cocoa flavanols intervention. Participants will take two capsules daily of placebo. The placebo will be a cellulose based capsule and will not contain cocoa flavanols or (-)-epicatechin.
Study: NCT06489236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccine Confidence: Skills to Promote Vaccination in the Pediatric Consultations
Description: Intervention mapping principles guided a multidisciplinary team through the development of the intervention. The intervention is a 12-hour training program focused on improving vaccination promotion and vaccine hesitancy management during pediatric consultations. The program comprises 10 hours of online education and 2 hours of in-person activities. Online training materials (short video lectures, video case studies, and readings) were structured in three learning modules covering vaccine and vaccine hesitancy technical information, vaccination promotion communication strategies, and practice organizational resources. In-person activities involved role-playings and group discussions. Intervention content is evidence-based. As a participation incentive, pediatric nurses and pediatricians who complete all program activities, including a multiple-choice final test, will receive 2,5 accredited continuing medical education credits.
Study: NCT05717660

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: SBRT on all sites of metastatic disease+Apalutamide
Description: oral Apalutamide 240 mg daily+ stereotactic body radiotherapy on all metastatic sites of disease, administered in 1-8 fractions for a total EQD2 of 50 Gy with an alpha/beta of 10.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT on all sites of metastatic disease+Apalutamide
Description: oral Apalutamide 240 mg daily+ stereotactic body radiotherapy on all metastatic sites of disease, administered in 1-8 fractions for a total EQD2 of 50 Gy with an alpha/beta of 10.
Study: NCT06372210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IEM tablet
Description: Oral placebo-embedded IEM tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abilify MyCite®
Description: Oral aripiprazole-embedded IEM tablet.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D-Tect Patch
Description: The D-Tect patch is a wearable sensor (WS) capable of detecting the ingestion of the IEM and measuring physiologic parameters. The WS automatically logs and stores the time when the IEM reaches the stomach and transmits the data to a smartphone.
Study: NCT04905628

Intervention type: DEVICE
Intervention: Dexcom CGM System
Description: Dexcom CGM System
Study: NCT05146830

Intervention type: OTHER
Intervention: Safety and Efficacy Assessments
Description: Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
Study: NCT06581029

Intervention type: OTHER
Intervention: The multidimensional peer victimization scale (PVS)
Description: The multidimensional peer victimization scale (PVS), a self-report scale for children and adolescents, was used to assess the victimization
Study: NCT05084924

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus
Description: Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus
Description: Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus
Description: Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
Study: NCT05491486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Group Therapy
Description: see above
Study: NCT05291338

Intervention type: DRUG
Intervention: Doxorubicin
Description: no optimal dosage of doxorubicin in TACE procedures (ranging from 30 to 75 mg/m2 up to a maximum of 150 mg/m2 ) according to tumor size